A clinical trial, funded by the National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK) revealed closed-loop artificial pancreas were better at controlling patients’ blood glucose levels than existing treatments.
The artificial pancreas allows for ‘closed-loop’ control which tracks blood glucose levels constantly with a continuous glucose monitor (CGM) and automatically delivers insulin via an insulin pump to the patient when required. Continuous monitoring and automatic regulation can be particularly useful for patients with type 1 diabetes, as glucose levels can drop to dangerously low levels throughout the night while the patient is sleeping.
“Artificial pancreas systems offer the ability to not only improve glycemic control but also ease the daily burden of blood sugar management that people with type 1 diabetes have to continually navigate,”
— Sue A. Brown, MD from University of Virginia, Study Co-Lead Author
In iData’s most recent report on U.S. and European (15 countries) market analysis for Diabetes | 2019-2025 | MedSuite, the European diabetes monitoring, treatment, and drug delivery market was valued at €6.8 billion in 2018. This is expected to increase over the forecast period at a CAGR of 4.3% to exceed €9 billion. The U.S. diabetes monitoring, treatment, and drug delivery market was valued at $15.7 billion in 2018 and expected to increase at a CAGR of 0.6% to reach $16.4 billion by 2025.
For Further Information
To get in an in-depth U.S. and European market analysis which includes interviews and procedural volumes, check out iData Research’s 754 page study titled the Diabetes Market Analysis, Size, Trends | 2019-2025 | MedSuite
